Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Earning Call held on February 4, 2022 for discussion on unaudited financial results for quarter and nine months ended December 31, 202108-02-2022
08-02-2022
Buy Shalby; target of Rs 170: ICICI Direct
ICICI Direct is bullish on Shalby has recommended buy rating on the stock with a target price of Rs 170 in its research report dated February 07, 2021.07-02-2022
Earnings Call for Q3FY22 of Shalby Ltd
Conference Call with Shalby Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.04-02-2022
Shalby Ltd - 540797 - Financial Results With Segment Reporting For The Quarter And Nine Months Ended December 31, 2021
With reference to outcome of Board Meeting as submitted vide above referred letter, please find attached herewith financials statement along with Segment wise information, which was missing in our earlier submission. Please note that we have already uploaded the same in XBRL mode on NSE - NEAPs and BSE Listing Centre on February 2, 2022. There is no change in any of the financial figures submitted earlier.04-02-2022
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed herewith the copies of advertisement published on February 3, 2022 in Financial Express (English and Gujarati) for Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2021.03-02-2022
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on financial & operational performance for quarter ended 31st December 202103-02-2022
Q3FY22 Quarterly Result Announced for Shalby Ltd.
Healthcare Facilities company Shalby declares Q3FY22 result: Total Revenues of Rs. 1,531 million up by 16.2%, EBITDA of Rs. 312 million with margins of 20.4% Performance backed by growth in core business, surgery count up by 84% to 5,679 in Q3 FY22 compared to 3,082 in Q3 FY21 Total Revenues of Rs. 1,531 million, growth of 16.2% Operating EBITDA of Rs. 312 million with EBITDA margins of 20.4% Profit Before Tax and Exceptional Items was Rs. 215 million, margins of 14.0% Bed occupied during the quarter were 513, with occupancy rate of 42% In patients count increased 17% y-o-y, driven by increase in non-covid patients Mr. Shanay Shah, President said: “I am happy to report that Shalby has surpassed full year FY21 hospital business numbers in 9M FY22 with Revenue, EBIDTA and PAT of Rs.5,075 million, Rs. 1,103 million and Rs.541 million respectively. Our Q3 FY22 performance was backed by increase in surgery count by 84% y-o-y to 5,679. Our occupancy levels remained stable at 42% and ARPOB also recovered to Rs.32,049 as compared to Rs.26,660 with pick-up in elective surgeries and almost no contribution from COVID-19 patients. Generally, third quarter of a year is always moderate due to festivities however, we have recorded the highest revenue numbers for any Q3 in our history. During the quarter, Shalby (hospital business) recorded total revenues of Rs. 1,531 million, growth of 16% on y-o-y, EBIDTA was Rs. 312 million with margins remaining strong at 20.4%. Profit before tax was Rs. 215 million with margin of 14.0%. In Q3 FY22, Arthroplasty, Critical care & General Medicine, Cardiac Science Oncology, Orthopedic, and Neurology contributed 38%, 11%, 10%, 10%, 9% and 6% to the revenues respectively. Although Shalby continues to maintain leadership position in Arthroplasty, it has also transformed itself as a multispecialty hospital with diversified revenue mix.” Result PDF02-02-2022
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Copy of press release on the Unaudited Financial Results for the quarter and Nine Months ended on December 31, 202102-02-2022
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that Investor/ Analyst Conference call is scheduled on Friday, February 4, 2022 at 4:00 p.m. to discuss unaudited Financial Results for quarter and nine months ended December 31, 2021 as per schedule mentioned in the invitation attached herewith.02-02-2022
Shalby Ltd - 540797 - Disclosure Under Regulation 30 (5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Disclosure Under Regulation 30 (5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.02-02-2022